Title: Study of Correlation of Lipid Profile and HbA1C in Diabetic Complications
Authors: B. Jyothirmayi, V.M. Vinodhini
DOI: https://dx.doi.org/10.18535/jmscr/v7i2.64
Abstract
Aim: The aim of the study was to assess the association of lipid profile with HBA1C in diabetic complications.
Materials and Methods: For our study 50 type 2 diabetes mellitus patients with complications were included as study group and 50 type 2DM patients without complications as controls. The study was conducted at SRM Medical college Hospital and Research centre, Kattankulathur, Chennai. Fasting sample was collected and processed for plasma sugar, lipid profile and HbA1C.
Results: Significant correlation was found between total cholesterol, triglycerides, LDL. Correlation was not significant was between HDL and HbA1C even though there was decrease in HDL levels compared to control group.
Conclusion: Dyslipidemia with poorly controlled blood sugar levels are contributors for diabetic complications, which can be prevented by regular monitoring of blood sugar levels and lipid profile.
Keywords: Dyslipidemia, HbA1C, Diabetes complications.
References
- Bhambhani GD, Bhambhani RG, Thakor NC. Lipid profile of patients with diabetes: a cross-sectional study. Int Journal of Med Sci 2015;3:3292-3295.
- International Diabetes Federation (IDF) 2015. Gadi R, Samaha FF. Dyslipidemia in type 2 diabetes mellitus. Curr diab Rep2007;7(3): 228-234
- Khan SR, Ayub N, Nawab S, Shamsi TS. Triglyceride profile in dyslipidemia of type 2 diabetes mellitus. J Coll Phys Surg Paj.2008;18(5):270-273.
- Shera A, Jawad F. Prevalence of chronic complications and associated factors in type 2 diabetes. J Pak Med Assoc2004;54: 54-9.
- Wexler DJ, Grant RW, Meigs JB, Nathan DM, Cagliero E. Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. Diabetes Care. 2005;28(3):514–520.
- Regmi P, Gyawali P, Shrestha R, Sigdel M, Mehta KD, Majhi S. Pattern of dyslipidemia in type-2 diabetic subjects in Eastern Nepal. J Nepal Assoc Med Lab Sci. 2009;10(1):11–13.
- Austin MA, King MC, Vranizan KM, Krauss RM: Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation 82:495–506, 1990.
- Campos H, Genest JJ Jr, Blijlevens E, McNamara JR, Jenner JL, Ordovas JM, Wilson PWF, Schaefer EJ: Low density lipoprotein particle size and coronary artery disease. Arterioscler ThrombVasc Biol/12:187–195,1992
- Lamarche B, Depres JP, Moorjani S, Cantin B, Dagenais GR, Lupien PJ: Triglycerides and HDL-cholesterol as risk factors for ischemic heart disease: results from the Quebec Cardiovascular Study. Atherosclerosis 119:235–245, 1996.
- Selvin E, Meta Analysis: Glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Annals of Internal Medicine.2004;141:421
- Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care. 2004;27(6):1496–1504.
- Howard BV. Lipoprotein metabolism in diabetes mellitus. J Lipid Res. 1987;28(6):613–628.
- Taskinen MR, Kahri J, Koivisto V, Shepherd J, Packard J. Metabolism of HDL apolipoprotein A-I and A-II in type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1992;35(4):347–356.
- Shih, K.C., Kwak, C.F and Hwa , C.M (1997). Acipimox alternates hypertriglyceridemia in dyslipidemic NIDDM patients without perturbation of insulin sensitivity and glycemic control. Diabetic .Res. Clin.Pract 36(2),113-19.